Some of the statements herein may be forward-looking statements involve risks and uncertainties online pharmacy . Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors that could cause actual results, performance or achievements of Aethlon Medical, Inc may cause in terms materially different from any future results, performance or achievements or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the Company’s ability to raise capital when needed obtain, the Company’s ability to complete the development of the planned products, the ability of the company, FDA and other regulatory approvals to allow to sell their products, the Company’s ability products products and its services, the impact of government regulations, patent protection on the Company ‘s proprietary technology, product liability exposure, Uncertainty of market acceptance, competition, technological change, and other risk factors. In such cases, the actual results as a as a result of numerous factors, including the risks associated with the effect of changing economic conditions and other risk factors that are filed in the Company’s filings with the Securities and Exchange Commission in detail.
Aethlon Medical Hemopurifie the developer of a first – in-class medical device is designed to treat infectious diseases. Which provides real-time therapeutic Hemopurifie filtration of infectious viruses and immunosuppressive particles and is positioned to address the treatment of drug resistant virus and vaccine. Additionally, the device holds promise in cancer treatment, as studies have demonstrated the Hemopurifie can capture immunosuppressive particles tumors tumors. The Hemopurifie both as a standalone as a standalone therapy and as an adjunctive treatment to improve clinical benefit of established therapies. Preclinical studies of researchers representing leading government and non – government health organizations were conducted both in the United States and abroad, the efficacy of the Hemopurifie in capturing from circulation the viruses that pandemics, including H5N1 Avian Influenza form , documented and dengue haemorrhagic fever from circulation. The company is carrying out studies, from the U.S. Food use of Hemopurifie as broad-spectrum treatment countermeasure against bioterror threats, including smallpox and Ebola, Marburg and Lassa hemorrhagic fever. Regulatory and commercialization initiatives in the United States are presently focused on bioterror threats, while international initiatives toward naturally evolving pandemic threats, and chronic infectious disease conditions including the Human Immunodeficiency Virus and hepatitis C are addressed. Aethlon demonstrated the safety of the Hemopurifie in a 24 – treatment human study at the Apollo Hospital in Delhi, and is currently conducting further human studies at the Fortis Hospital in Delhi. The Company has filed an Investigational Device Exemption from the U.S. Food and Drug Administration Hemopurifie Hemopurifie as broad-spectrum treatment countermeasure against category ‘A’bioterror threats. Additional information regarding Aethlon Medical and its Hemopurifie technology is available online at.
According to researchers, an increase in the satisfaction with law over the years ‘expected as the shrink for to be more familiar with the to the procedures and formalities at ‘. However the survey reveals to essential areas of concern. Writing at the Psychiatric Bulletin , the researchers said: ‘Although there may be to a further improvement a further improvement in future, of course, there a significant level of unhappiness with the Act present to 43 percent of respondents dissatisfied or very dissatisfied. In the second study, there was one statistically significant increase respondents who feel patient care was improved, but 69 percent of psychiatrists continues to believe to is not patient care expressed enhanced with this new law. , however, addition, the great majority had been the psychiatrist in 2007 interviewed Your daytime load did raised due the new Act – with some of blame ‘excessively bureaucratic and time-consuming ‘red tape Another 40 percent reported on a increase in their. Out-of hours workloads.